Opaleye management, 10% owner, buys $136,177 Grace Therapeutics (GRCE)

Investing.com reports that Opaleye Management Inc., a 10% owner and director of Grace Therapeutics (GRCE), has increased its stake in the company by purchasing $136,177 worth of shares across multiple transactions between October 14 and October 16, 2026. The company traded at approximately $1.89, close to its 52-week low of $1.79, and analysts consider it undervalued with price targets ranging from $3.92 to $7.88.

Opaleye Management acquired 11,233 shares on October 14 at an average price of $1.9349, followed by 23,485 shares on October 15 at $1.9453, and finally 36,347 shares on October 16 at $1.8917. After these purchases, the firm now owns a total of 2,944,354 shares of GRCE common stock.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.